ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use

First phase of development of product to reduce risk of variant Creutzfeldt-Jakob Disease from plasma product completed on schedule

25-Jan-2008

ProMetic Life Sciences Inc. announced that its UK-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has successfully completed the first phases of development utilizing Pathogen Removal and Diagnostic Technologies Inc.'s ("PRDT") ligand technology for prion binding and removal from a plasma product for biopharmaceutical use marketed by a major European plasma fractionator. The program, which is progressing on schedule with expected completion of the scale-up phase in June 2008, is worth approximately $ 1 M to ProMetic. This will be followed by a multi-million dollar long-term supply agreement for the prion reduction resin. The supply agreement is in final stage of negotiation and commercial quantities of resin supply could commence as soon as mid-2008, assuming regulatory approval of the product.

The incorporation in this new application of PRDT's proprietary ligand technology, which is licensed exclusively to PBL, ensures the removal of any abnormal prion proteins that may be present in donated plasma. This additional process will add another level of safety to the already established treatment protocols and is particularly relevant since there is no commercially available diagnostic test for detection of the blood-borne form of the variant Creutzfeldt-Jakob disease ("vCJD") agent.

https://www.bionity.com/en/news/76953/prometic-announces-scale-up-of-prion-removal-resin-in-plasma-product-for-biopharmaceutical-use.html